Lithuania Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Lithuania Pharmaceuticals & Healthcare Report

The Lithuania Pharmaceuticals and Healthcare Report

Independent 5-year pharmaceutical and healthcare industry forecasts for Lithuania.

Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Lithuanian pharmaceutical and healthcare industry.

Competitive intelligence, Lithuanian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Lithuanian market.

The Lithuania Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Lithuania Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Lithuanian pharmaceutical and healthcare industry.

Key Benefits of Report

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Lithuania Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Table of Contents

Chapter - Executive Summary

Lithuania Pharmaceuticals And Healthcare Industry SWOT
Political SWOT
Economic SWOT
Business Environment SWOT

Chapter - Pharmaceutical Business Environment Ratings

Table: Regional Pharma Business Environment Ratings
Limits of Potential Returns
Risk to Realisation of Returns

Chapter - Lithuania – Market Summary

Regulatory Regime
Regional Collaboration
Recent EU-Wide Regulatory Developments
Adherence Mandator
Intellectual Property Developments
Pricing Regime
Reimbursement Regime

Chapter - Industry Developments

Epidemiology
Table: Selected Health Indicators For Lithuania, 1995-2004
Healthcare System
Table: Healthcare Facilities And Personnel In Lithuania, 1995-2005
Healthcare Funding
Healthcare Insurance
Corruption
Pharmaceutical Industry
Table: Drugmakers, Distributors And Retailers Active In The Baltic States, Q207
Recent Pharmaceutical Industry Developments
Pharmaceutical Wholesale And Distribution
Pharmaceutical Retail
Biotechnology
Clinical Trials
Medical Devices

Chapter - Industry Forecast Scenario

Overall Market Forecast
Table: Lithuania - Drug Expenditure Indicators, Historical Data and Forecasts
Key Growth Factors – Industry
Table: Lithuania - Healthcare Expenditure Indicators, Historical Data and Forecasts
Key Growth Factors – Macroeconomic
Recession Ahead In 2009
Table: Lithuania – Economic Activity
Prescription Market Forecast
Table: Lithuania - Prescription Market Indicators, Historical Data and Forecasts (LTLmn unless otherwise stated)
Patented Market Forecast
Table: Lithuania – Patented Drug Market Indicators, Historical Data And Forecasts
Generics Market Forecast
Table: Lithuania – Generics Market Indicators, Historical Data And Forecasts
OTC Market Forecast
Table: Lithuania – OTC Market Indicators, Historical Data And Forecasts (LTLmn unless otherwise stated)
Export/Import Forecasts
Table: Lithuania – Pharmaceutical Trade, Historical Data And Forecasts (US$mn)
Other Healthcare Data Forecasts
Table: Lithuania - Other Healthcare Indicators, Historical Data And Forecasts
Key Risks To BMI's Forecast Scenario

Chapter - Competitive Landscape

Company Monitor
Multinational Company Profiles
GlaxoSmithKline
Pfizer
Novartis
Merck & Co
Sanofi-Aventis
Indigenous Company Profiles
Valentis
Sanitas
Sicor Biotech

Chapter - Country Snapshot: Lithuania Demographic Data

Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2000-2012

Chapter - BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Lithuania Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Executive Summary

In the BMI‘s Business Environment Ranking matrix for Q209, Lithuania’s position has worsened from 11th to 13th out of the 20 main markets surveyed in Central and Eastern Europe (CEE) (which now include Moldova and Belarus). The change was due to a lower overall score, as the country struggles with economic downturn and slowdown in exports. Nevertheless, Lithuania’s pharmaceutical market is likely to experience a better compound annual growth rate (CAGR) than its Baltic neighbour Latvia. By 2013, the market will reach the valuation of LTL1.49bn (US$552mn), growing at a CAGR of 3.72% in local currency terms. This is a decrease from the 2008 level of LTL1.24bn (US$511mn).

While the government is likely to undertake significant reductions in public spending over the coming year, in January 2009 the local press reported that Lithuania will receive a funding of some EUR0.34mn (US$0.44mn) from Switzerland. This would be as part of an international cooperation agreement. A large part of the fund will be used for developing Lithuania's healthcare system, which includes the improvement of hospital infrastructure, healthcare services offered to pregnant women, and the development of fundamental science research.

On the company news front, there have been relatively few major developments. A new production facility in the city of Kaunas – which had been inaugurated in October 2008 by leading domestic pharmaceutical producer, Sanitas – was inspected by the State Medicines Control Agency in early 2009. The plant received a good manufacturing practice (GMP) certification, with Sanitas planning to diversify its product range and increase its export activities, given the limited opportunities in its home market.

In the meantime, pharmaceutical companies operating across the European Union (EU) (of which Lithuania is a member), the recent adoption of a proposal for harmonising the rules and procedures related to changing marketing authorisations should work towards facilitating of market access. The directive amendment would make all medicines – including those authorised through a national approval route – subject to a single set of legislation. This is a development welcomed by a number of European manufacturers’ associations. The proposal is part of a global revision of EU regulatory framework, which should minimise Bloc-wide variations in national rules, and also further encourage the use of the EU's mutual recognition process for the approval of initial marketing authorisations of medicines.

Lithuania Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Read about our other Pharmaceuticals & Healthcare Reports

Africa

Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe

Asia

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam

Caribbean

Puerto Rico

Europe

Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan

Latin America

Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela

Middle East

Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates

North America

Canada and United States
Business Monitor International Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 25 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.